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Discuss the operational impacts of the onboard pharmacy
Discuss risks associated with the inability to supply a safe, 
robust, and comprehensive formulary for long-duration 
spaceflight outside of low-Earth orbit (LEO)
Discuss implications of these risks
Discuss potential mitigation strategies to address this risk
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Introduction
Concerns/Risks
Implications
Potential Solutions
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Pharmaceutical intervention is essential component of risk 
management for astronaut healthcare during exploration 
spaceflight
Historically, medication use has not been comprehensively 
monitored (largely due to crew time constraints)
Currently, certain medications can be used without prior 
consultation with a flight surgeon (e.g. OTCs for headache or 
congestion)
Such use may be reported during weekly Private Medical 
Conferences (PMCs), but there is currently no requirement to 
do so
However, due to delayed reporting, information such as 
indication, dose, timing, or side effects may not be reported or 
recorded
Introduction
4
Medication use reporting has improved over time (as discussed 
by previous presenter)
Common complaints: headache, congestion, sleep disturbance, 
space motion sickness
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With stricter reporting, the significance of an on-board pharmacy 
becomes clear
NASA's Human Research Roadmap (HRR) identifies medication use as 
a potential countermeasure for prevention or management of several 
conditions
• Examples include:
– Potassium citrate for nephrolithiasis prophylaxis
– Pain medication for EVA-induced pain or injuries
– Antidepressants or antipsychotics for adverse cognitive or behavioral 
conditions and psychiatric disorders
– Bisphosphonates for bone fracture due to spaceflight-induced changes to 
bone
 In analysis of medical capabilities needed for a Mars transit mission, 
NASA’s Exploration Medical Capability (ExMC) element preliminarily 
identified onboard pharmacy as the largest single component of a 
complete medical system (>25% of all medical interventions)
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Anecdotal evidence that medications may be less efficacious in 
spaceflight
• Space Shuttle – Putcha (1999)
– 13 different medications “not effective” or “mildly effective”
• Space Shuttle/ISS – Barger (2014)
– Sleep medication – 17-19% of cases required second dose
Medication stability
• 87% of medications flown on ISS have shelf lives <24 months
• Many may be repackaged to save weight/volume, especially for 
exploration missions
• Radiation can play a role in degradation of API (active 
pharmaceutical ingredient)
• Significant limitation for exploration-class missions
Concerns/Risks
7
PK/PD may be altered
• Pharmacokinetics (body effects on medications)
• Pharmacodynamics (medication effects on body)
Altered microbial growth and antimicrobial susceptibility
Inability to evacuate to Earth quickly
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Bottom Line:
• These concerns/risks may lead to a medication being unavailable 
when needed without the ability to resupply or evacuate the 
patient
• Without a safe and comprehensive on-board pharmacy, may not be 
able to fully address certain medical issues in an astronaut during 
an exploration-class mission
If unable to fully treat medical condition:
• Potential performance decrements that could impact successful 
completion of science and/or mission
• Additional time/resources in space and on the ground devoted to a 
problem that may have been rectified with appropriate medication
• Use of sub-optimal medication to manage condition may mean that 
this medication is unavailable to treat another better-suited issue 
later in the mission
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Goal: Supply a safe, robust, and comprehensive pharmacy for 
long-duration spaceflight outside of LEO
Standardized documentation or medication tracking to provide 
better physician awareness and allow for more accurate 
inventory management
Better medical condition/risk prediction in order to 
appropriately weigh trades when optimizing the on-board 
exploration medical system
Investigation/research into:
• Stability and/or shelf-life extension
• Ground-based radiation exposure
• PK/PD
Potential Solutions
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